Zydus Cadila gets USFDA's final approval for Meclizine Hydrochloride Tablets

24 Jun 2020 Evaluate

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Meclizine Hydrochloride Tablets (US RLD: AntivertTM Tablets) in the strengths of 12.5 mg and 25 mg. Meclizine is an antihistamine that is used to prevent and treat nausea, vomiting, and dizziness caused by motion sickness. It may also be used to reduce dizziness and loss of balance (vertigo) caused by inner ear problems.

The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The group now has 292 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.


Zydus Lifesciences Share Price

923.90 2.65 (0.29%)
16-Dec-2025 10:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1781.50
Dr. Reddys Lab 1273.50
Cipla 1500.40
Zydus Lifesciences 923.90
Lupin 2089.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×